“…Not to be overlooked is the fact that 3 times as many patients with nACHD receive pretransplant VADs that can dually reverse end-organ dysfunction (eg, liver, kidney) and minimize the need for inotropic support. 12 This treatment additionally may allow select patients more mobility and, with further therapies, an opportunity to lose weight. 13,14 Further, it could allow for cardiac rehabilitation before transplantation.…”